Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

This lawsuit is for anyone who acquired securities in Atara Biotherapeutics, Inc. (NASDAQ: ATRA) from May 20, 2024 through January 9, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the FDA was likely to approve the Company’s Biologics License Application (“BLA”) for the Company’s Epstein-Barr treatment, tabelecleucel, when the CompaNy knew FDA approval was unlikely because of certain manufacturing issues, as well as deficiencies inherent in the ALLELE study.

On January 16, 2025, Atara disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) of the Company’s Epstein-Barr treatment, tabelecleucel (also referred to as EBVALLO), and that the application would not be approved in its current form, stating that “[t]he CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on January 21, Atara disclosed that the FDA had “placed a clinical hold on Atara’s active Investigational New Drug (IND) applications” due to “inadequately addressed GMP [good manufacturing practice] compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the [CRL]” issued in connection with the tabelecleucel BLA. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume. Finally, on January 12, 2026, Atara disclosed that the FDA had issued another CRL regarding the resubmitted tabelecleucel BLA stating that “[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form” because “the single arm ALLELE trial . . . is no longer considered to be adequate to provide evidence of effectiveness for accelerated approval” and “the trial’s interpretability is confounded due to trial study design, conduct, and analysis.” On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Atara Biotherapeutics, Inc. (NASDAQ: ATRA) from May 20, 2024 through January 9, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.